If you meet any of these indications, please contact us at
800 390 390
TromboGen Gravidity®
Reveals the risk of pregnancy complications
The TromboGen Gravidity® genetic analysis can detect risk predispositions for increased blood clotting, which can significantly contribute to reducing the risk of thrombosis and related pregnancy complications. Pregnant women are at risk of developing thrombosis, or a blood clot, much more than other women of the same age. This is due to the physiological changes that occur during pregnancy and possible hereditary dispositions.
In which situations it is appropriate to take the test
PUBLIC HEALTH INSURANCE COVERS THE TEST IN THE FOLLOWING SITUATIONS
- For women who have had 3 spontaneous abortions in the first trimester of pregnancy, or for any fetal loss later in pregnancy.
- For pregnant women if they have had TED or if a first-degree blood relative has had TED.
- For pregnant women in the case of pre-eclampsia, fetal growth retardation or placental abruption.
- For patients with a personal history of idiopathic thromboembolic disease (TED).
- Before starting hormonal contraceptives or hormone replacement therapy in women who have had TED or if any of their first-degree blood relatives have had TED.
- In the presence of Leiden or prothrombin mutations in first-degree relatives (testing of children is performed after the age of 12 years, in exceptional cases earlier).
DETAILED INFORMATION
Pregnant women have up to 5 times higher risk of developing deep vein thrombosis compared to non-pregnant women (up to 20 times higher in the puerperium). This is mainly due to:
- Physiological changes - blood flow in the veins slows down, there may be compression of the venous wall in the pelvic area by the growing uterus.
- Increased blood clotting - there is an increase in pro-clotting factors and suppression of anti-clotting mechanisms (the body prepares the woman for childbirth,
which could put her at risk of blood loss). - Inherited factors - the so-called congenital thrombophilias (Leiden mutation of the F5 gene and prothrombin mutation of the F2 gene) occur in 5-10% of the population.
In pregnancy, thrombophilic mutations pose an increased risk of spontaneous abortion, premature placental abruption, fetal growth retardation (IUGR), and other complications. The TromboGen Gravidity® genetic analysis can screen for risk thrombophilic mutations that are involved in blood clotting and can make a significant contribution to preventing venous thrombosis and minimizing potential complications for you and your unborn baby.
The TromboGen Gravidity® genetic analysis detects thrombophilic mutations (Leiden mutation of the F5 gene and prothrombin mutation G20210A of the F2 gene), including examination of the M2 haplotype of the ANXA5 gene. Mutation of the F5 or F2 gene puts pregnant women at increased risk of complications, especially spontaneous abortion, premature placental abruption, fetal growth retardation and venous thrombosis. The M2 haplotype of the ANXA5 gene prevents blood clots, especially in the placenta, and mutations in the ANXA5 gene can lead to complications in pregnancy, such as spontaneous abortion, pre-eclampsia, low birth weight, venous thrombosis and others. If a genetic predisposition is proven in a pregnant woman, she is recommended appropriate prevention and regular monitoring during pregnancy.
HOW DOES THE WHOLE PROCESS WORK?
After ordering the test, you will receive an email with detailed information. A DNA sample is most often obtained through an oral swab or blood sample. You can perform the oral swab yourself in the comfort of your own home using a collection kit which will be sent to you by mail together with instructions and other documents. You can have your blood drawn at your local physician's office or at our outpatient clinic. The result of the analysis will be sent to you by e-mail or by post as agreed. In the case of a positive result, we recommend an appointment for a genetic consultation.